During the last session, AnaptysBio Inc (NASDAQ:ANAB)’s traded shares were 0.48 million, with the beta value of the company hitting 0.02. At the end of the trading day, the stock’s price was $16.85, reflecting an intraday gain of 1.32% or $0.22. The 52-week high for the ANAB share is $41.31, that puts it down -145.16 from that peak though still a striking 25.76% gain since the share price plummeted to a 52-week low of $12.51. The company’s market capitalization is $512.72M, and the average intraday trading volume over the past 10 days was 0.85 million shares, and the average trade volume was 716.75K shares over the past three months.
AnaptysBio Inc (ANAB) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.55. ANAB has a Sell rating from 0 analyst(s) out of 6 analysts who have looked at this stock. 3 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 3 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -1.7.
AnaptysBio Inc (NASDAQ:ANAB) trade information
AnaptysBio Inc (ANAB) registered a 1.32% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 1.32% in intraday trading to $16.85, hitting a weekly high. The stock’s 5-day price performance is 12.11%, and it has moved by 15.81% in 30 days. Based on these gigs, the overall price performance for the year is -29.88%. The short interest in AnaptysBio Inc (NASDAQ:ANAB) is 7.33 million shares and it means that shorts have 9.29 day(s) to cover.
The consensus price target of analysts on Wall Street is $40, which implies an increase of 57.88% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $19 and $90 respectively. As a result, ANAB is trading at a discount of -434.12% off the target high and -12.76% off the low.
AnaptysBio Inc (ANAB) estimates and forecasts
Statistics show that AnaptysBio Inc has underperformed its competitors in share price, compared to the industry in which it operates. AnaptysBio Inc (ANAB) shares have gone down -54.34% during the last six months, with a year-to-date growth rate less than the industry average at 0.00% against 16.50. In the rating firms’ projections, revenue will increase 225.96% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 7.79M as predicted by 11 analyst(s). Meanwhile, a consensus of 9 analyst(s) estimates revenue growth to 8.36M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 9.01M and 7.18M respectively. In this case, analysts expect current quarter sales to shrink by -13.54% and then jump by 16.39% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -19.45%. While earnings are projected to return -0.07% in 2025, the next five years will return 4.19% per annum.
ANAB Dividends
AnaptysBio Inc is due to release its next quarterly earnings in February. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
AnaptysBio Inc (NASDAQ:ANAB)’s Major holders
AnaptysBio Inc insiders own 1.74% of total outstanding shares while institutional holders control 116.85%, with the float percentage being 118.92%. ECOR1 CAPITAL, LLC is the largest shareholder of the company, while 228.0 institutions own stock in it. As of 2024-06-30, the company held over 7.52 million shares (or 27.4931% of all shares), a total value of $188.48 million in shares.
The next largest institutional holding, with 2.87 million shares, is of FMR LLC’s that is approximately 10.4936% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $71.94 million.
Also, the Mutual Funds coming in first place with the largest holdings of AnaptysBio Inc (ANAB) shares are Vanguard Total Stock Market Index Fund and Fidelity Small Cap Growth Fund . Data provided on Sep 30, 2024 indicates that Vanguard Total Stock Market Index Fund owns about 733.95 shares. This amounts to just over 2.41 percent of the company’s overall shares, with a $12.37 million market value. The same data shows that the other fund manager holds slightly less at 625.15, or about 2.05% of the stock, which is worth about $10.53 million.
